Sign up to save your podcasts
Or
Share Generic Competition for Dimethyl Fumarate
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Generic Competition for Dimethyl Fumarate
Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the full article at 46brooklyn.com.
To hear the full podcast: https://www.neurology.org/podcast
View all episodes
By American Academy of Neurology
4.8
129129 ratings
Dr. Jason Crowell talks with 46brooklyn Research CEO Antonio Ciaccia about how Medicare Part D has hidden the benefits of generic competition for Tecfidera, a disease-modifying therapy for multiple sclerosis. Read the full article at 46brooklyn.com.
To hear the full podcast: https://www.neurology.org/podcast
More shows like Neurology Minute
View all
JAMA Editors' Summary
129 Listeners
Neurology® Podcast
286 Listeners
NEJM This Week
319 Listeners
Practical Neurology Podcast
36 Listeners
JAMA Clinical Reviews
487 Listeners
JAMA Neurology Author Interviews
14 Listeners
JAMA Medical News
85 Listeners
Neurology Today in 5
23 Listeners
Annals On Call Podcast
181 Listeners
Navigating Neuropsychology
341 Listeners
The Clinical Problem Solvers
509 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
322 Listeners
Neurology Exam Prep Podcast
180 Listeners
The Curious Clinicians
361 Listeners
Continuum Audio
78 Listeners